Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study.

Claire C ConleyMcKenzie McIntyreNicole A PensakFilipa LynceDeena GrahamRoohi Ismail-KhanKatherine LopezSusan T VadaparampilSuzanne C O'Neill

Published in: Breast cancer research and treatment (2022)

Barriers to adherence to CDK4/6 inhibitors exist at multiple levels. Our results underscore the potential value of a multilevel intervention (e.g., patient education, evidence-based strategies for symptom management, tips for open and assertive communication with providers, information about financial resources/support available, and so on) to support adherence in this population.

Keyphrases

metastatic breast cancer
cell cycle
randomized controlled trial
healthcare
case report
minimally invasive
quality improvement
glycemic control
health information
cell proliferation
metabolic syndrome
human health
adipose tissue
climate change
health insurance
patient reported